
- Remove this product from my favorite's list.
- Add this product to my list of favorites.
Products
Newsletter
![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Background: Cediranib is a highly potent and orally available tyrosine kinase inhibitor (TKI), targeting VEGF receptor; thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth.
Chemical formula: C25H27FN4O3
Molecular weight: 450.51 g/mol
Purity: 99%
Appearance: Off-white Solid
Solubility: Soluble in DMSO
CAS Number: 288383-20-0
Manufacturer: Axon Medchem BV
PLEASE NOTE: This product is designed for research purposes and can only be delivered to academic and business customers.
SR Wedge et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005, 65 (10), 4389–400.
G Goss et al. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine. Eur. J. Cancer 2008, 45, 782.
P Nikolinakos & JV Heymach. The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. J. Thorac. Oncol. 2008, 3 (6 Suppl 2): S131–4.
CA Heckman et al. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res. 2008, 68(12), 4754-4762.
Recombinant Vascular endothelial growth factor receptor 2 (VEGF-R2), protein kinase domain, 10 µg - 295,00 €
Recombinant Vascular endothelial growth factor receptor 1 (VEGF-R1), protein kinase domain, 10 µg - 295,00 €
Protein tyrosine kinase inhibitor GW 786034, 5 mg - 110,50 €
Protein tyrosine kinase inhibitor Vandetanib, 25 mg - 208,00 €
Protein kinase inhibitor AG 013736, 5 mg - 104,00 €
Welcome Login
Contact us
Follow us